TIBET DUO RUI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.5 CNY | +1.40% |
|
+13.17% | -26.88% |
| Sales 2022 | 401M 55.4M | Sales 2023 | 334M 46.18M | Capitalization | 2.13B 295M |
|---|---|---|---|---|---|
| Net income 2022 | 20M 2.76M | Net income 2023 | 18M 2.49M | EV / Sales 2022 | 5.44 x |
| Net cash position 2022 | 405M 55.88M | Net cash position 2023 | 303M 41.81M | EV / Sales 2023 | 5.48 x |
| P/E ratio 2022 |
124
x | P/E ratio 2023 |
111
x | Employees | 395 |
| Yield 2022 * |
-
| Yield 2023 |
0.47% | Free-Float | 28.85% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.40% | ||
| 1 week | +13.17% | ||
| Current month | -6.56% | ||
| 1 month | -6.56% | ||
| 3 months | -14.62% | ||
| 6 months | -29.25% | ||
| Current year | -26.88% |
1 week
17.67
19.65
1 month
15.1821.69
Current year
12.6027.56
1 year
12.6035.54
3 years
12.6054.55
5 years
12.6054.55
10 years
12.6054.55
| Managers | Title | Age | Since |
|---|---|---|---|
Yong Deng
CEO | Chief Executive Officer | 58 | 17-11-30 |
Chao Li
DFI | Director of Finance/CFO | 45 | 17-04-30 |
Fen Jin
BRD | Director/Board Member | 44 | 16-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Fei Liu
BRD | Director/Board Member | 46 | 20-02-20 |
Yong Deng
CEO | Chief Executive Officer | 58 | 17-11-30 |
Shao Zhong Zhang
BRD | Director/Board Member | 68 | 16-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 19.5 | +1.40% | 1,395,800 |
| 24-04-29 | 19.23 | +4.57% | 1,757,600 |
| 24-04-26 | 18.39 | +0.49% | 1,227,600 |
| 24-04-25 | 18.3 | +0.60% | 1,401,000 |
| 24-04-24 | 18.19 | +3.06% | 1,139,900 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Tibet Duo Rui Pharmaceutical Co Ltd is a company mainly engaged in the research and development (R&D), production and sales of chemical preparations and their active pharmaceutical ingredients (APIs). The Company's core product is sodium acetate ringer injection, which is mainly used to supplement body fluid, regulate electrolyte balance and correct acidosis. The Company's products also include its own products, compound electrolyte injection, compound mannitol injection and cefotaxime sodium for injection.
Sector
Pharmaceuticals
Calendar
2024-05-10
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -26.88% | 215M | |
| +31.03% | 699B | |
| +25.07% | 571B | |
| -4.70% | 364B | |
| +18.13% | 326B | |
| +2.68% | 286B | |
| +14.68% | 236B | |
| +4.71% | 198B | |
| -12.43% | 194B | |
| -4.44% | 154B |
- Stock Market
- Equities
- 301075 Stock
